Ann Pediatr Endocrinol Metab.  2019 Sep;24(3):180-186. 10.6065/apem.2019.24.3.180.

Cardiac autonomic neuropathy in nonobese young adults with type 1 diabetes

• Kim HY
• Jung HW
• Lee YA
• Shin CH
• Yang SW

• KMID: 2460765
• DOI: http://doi.org/10.6065/apem.2019.24.3.180

Abstract

PURPOSE
The aim of this study was to evaluate the prevalence and risk factors for cardiac autonomic neuropathy (CAN) in nonobese nonobese young type 1 diabetes mellitus (T1DM) patients without micro- or macrovascular complications.
METHODS
CAN was assessed in 95 patients with T1DM, aged 18-29 years, using standard cardiovascular reflex tests - heart rate response to deep breathing, standing, and the Valsalva maneuver and blood pressure response to standing. Furthermore, power spectral analyses of overall heart rate variability (HRV), standard deviation of NN intervals (SDNN), and total power (TP) were tested with DiCAN. CAN was defined as abnormal results for at least 1 of the 4 cardiovascular reflex tests.
RESULTS
The prevalence of CAN was 12.6%. The frequency of one and 2 abnormal reflex tests was 10.5% and 2.1%, respectively. No significant differences were observed in age, sex, mean hemoglobin A(1c) (HbA(1c)) level, and duration of diabetes with respect to presence of CAN. Patients with CAN exhibited lower overall HRV parameters (SDNN and TP) compared with those without CAN even though there was no statistical significance. In multivariable analyses, higher mean HbA(1c) level was significantly associated with lower overall HRV (β=-44.42, P=0.002 for SDNN and β=-2.82, P<0.001 for TP).
CONCLUSION
CAN can be detected in 12.6% of young adult T1DM patients even without other micro- or macrovascular complications. Glycemic control is the main determinant to maintain overall HRV and prevent CAN.

Keyword

Autonomic nervous system diseases; Type 1 diabetes; Prevalence; Risk factors; Young adult; Korea

MeSH Terms

Autonomic Nervous System Diseases
Blood Pressure
Diabetes Mellitus, Type 1
Heart Rate
Humans
Korea
Prevalence
Reflex
Reflex, Abnormal
Respiration
Risk Factors
Valsalva Maneuver
Young Adult*

Reference

References

1. Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013; 4:4–18.

2. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003; 26:1895–901.

3. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987; 59:256–62.

4. Stevens MJ, Raffel DM, Allman KC, Dayanikli F, Ficaro E, Sandford T, et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation. 1998; 98:961–8.

5. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed). 1982; 285:916–8.

6. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005; 28:956–62.

7. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996; 17:354–81.

8. Schönauer M, Thomas A, Morbach S, Niebauer J, Schönauer U, Thiele H. Cardiac autonomic diabetic neuropathy. Diab Vasc Dis Res. 2008; 5:336–44.

9. Tang M, Donaghue KC, Cho YH, Craig ME. Autonomic neuropathy in young people with type 1 diabetes: a systematic review. Pediatr Diabetes. 2013; 14:239–48.

10. Ziegler D, Gries FA, Spüler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications. 1992; 6:49–57.

11. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia. 1998; 41:416–23.

12. Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med. 2002; 19:900–9.

13. Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: risk factors, diagnosis and treatment. World J Diabetes. 2018; 9:1–24.

14. Dafaalla MD, Nimir MN, Mohammed MI, Ali OA, Hussein A. Risk factors of diabetic cardiac autonomic neuropathy in patients with type 1 diabetes mellitus: a meta-analysis. Open Heart. 2016; 3:e000336.

15. Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH, et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005; 48:164–71.

16. Stella P, Ellis D, Maser RE, Orchard TJ. Cardiovascular autonomic neuropathy (expiration and inspiration ratio) in type 1 diabetes. Incidence and predictors. J Diabetes Complications. 2000; 14:1–6.

17. Orchard TJ, LLoyd CE, Maser RE, Kuller LH. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Res Clin Pract. 1996; 34 Suppl:S165–71.

18. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019; 42(Suppl 1):S13–28.

19. Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012; 29:937–44.

20. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005; 293:217–28.

21. Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc. 2012; 87:1196–201.

22. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011; 27:639–53.

23. American Diabetes Association. 10. Microvascular complications and foot care: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41(Suppl 1):S105–18.

24. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH, et al. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care. 2008; 31:1360–6.

25. Spallone V, Bellavere F, Scionti L, Maule S, Quadri R, Bax G, et al. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis. 2011; 21:69–78.

26. Maser RE, Pfeifer MA, Dorman JS, Kuller LH, Becker DJ, Orchard TJ. Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of Diabetes Complications Study III. Arch Intern Med. 1990; 150:1218–22.

27. Kim GM, Woo JM. Determinants for heart rate variability in a normal Korean population. J Korean Med Sci. 2011; 26:1293–8.

28. Jaiswal M, Urbina EM, Wadwa RP, Talton JW, D'Agostino RB Jr, Hamman RF, et al. Reduced heart rate variability among youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care. 2013; 36:157–62.

29. Rosengård-Bärlund M, Bernardi L, Fagerudd J, Mäntysaari M, Af Björkesten CG, Lindholm H, et al. Early autonomic dysfunction in type 1 diabetes: a reversible disorder? Diabetologia. 2009; 52:1164–72.

30. Wawryk AM, Bates DJ, Couper JJ. Power spectral analysis of heart rate variability in children and adolescents with IDDM. Diabetes Care. 1997; 20:1416–21.

31. Tsuji H, Venditti FJ Jr, Manders ES, Evans JC, Larson MG, Feldman CL, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation. 1994; 90:878–83.

32. Singh JP, Larson MG, O'Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM, et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol. 2000; 86:309–12.

33. Ziegler D, Behler M, Schroers-Teuber M, Roden M. Nearnormoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. BMJ Open. 2015; 5:e006559.

34. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care. 2010; 33:434–41.

35. Andersen ST, Witte DR, Fleischer J, Andersen H, Lauritzen T, Jørgensen ME, et al. Risk factors for the presence and progression of cardiovascular autonomic neuropathy in type 2 diabetes: ADDITION-Denmark. Diabetes Care. 2018; 41:2586–94.

36. Orlov S, Cherney DZ, Pop-Busui R, Lovblom LE, Ficociello LH, Smiles AM, et al. Cardiac autonomic neuropathy and early progressive renal decline in patients with nonmacroalbuminuric type 1 diabetes. Clin J Am Soc Nephrol. 2015; 10:1136–44.

37. Straub RH, Zietz B, Palitzsch KD, Schölmerich J. Impact of disease duration on cardiovascular and pupillary autonomic nervous function in IDDM and NIDDM patients. Diabetes Care. 1996; 19:960–7.

38. Piha SJ, Halonen JP. Effect of disease duration on cardiac autonomic reflexes in young patients with insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1992; 18:61–7.